Dr. Lal Pathlabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025, Payable on or Before July 27, 2025
Published on 04/25/2025 at 05:03
Share
Dr. Lal PathLabs Limited at its board meeting held on April 25, 2025 announced the recommendation of final dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the financial year ended March 31, 2025, subject To Approve the Members of the Company at upcoming Annual General Meeting ("AGM"). The Final Dividend will be dispatched/credited within 30 days of the approval by the Members, if declared at the AGM, will be paid on or before July 27, 2025 to those members whose names appear in the Register of Members as on June 06, 2025 ("the Record Date").
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services in India. The Company offers patients and healthcare providers a range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its tests include Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, CBC Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Liver Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and Vitamin D Test. The Company has approximately 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore and Mumbai), 5,762 patient service centers (PSCs) and 11,619 pick-up points (PUPs). Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
